Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.
Rockville, US
Size (employees)
20 (est)
Rexahn Pharmaceuticals was founded in 2001 and is headquartered in Rockville, US

Rexahn Pharmaceuticals Office Locations

Rexahn Pharmaceuticals has an office in Rockville
Rockville, US (HQ)
15245 Shady Grove Road

Rexahn Pharmaceuticals Data and Metrics

Rexahn Pharmaceuticals Financial Metrics


Net income (FY, 2016)

(9.3 m)

EBIT (FY, 2016)

(16.4 m)

Market capitalization (28-Jun-2017)

76 m

Closing share price (28-Jun-2017)


Cash (31-Dec-2016)

11.6 m
Rexahn Pharmaceuticals's current market capitalization is $76 m.
USDFY, 2015FY, 2016

R&D expense

12.1 m10.1 m

General and administrative expense

6.1 m6.3 m

Operating expense total

18.3 m16.4 m


(18.3 m)(16.4 m)

Interest income

103.3 k118.6 k

Pre tax profit

(14.4 m)(9.3 m)

Net Income

(14.4 m)(9.3 m)
USDFY, 2015FY, 2016


10.2 m11.6 m


1.2 m608.5 k

Current Assets

24.7 m20.9 m

Total Assets

24.8 m21 m

Accounts Payable

2.7 m1.9 m

Additional Paid-in Capital

124.5 m132.1 m

Retained Earnings

(105.7 m)(115 m)

Total Equity

18.8 m17.1 m

Financial Leverage

1.3 x1.2 x
USDFY, 2015FY, 2016

Net Income

(14.4 m)(9.3 m)

Depreciation and Amortization

27.5 k32.9 k

Accounts Payable

202 k(778.8 k)

Cash From Operating Activities

(17.4 m)(13.2 m)

Purchases of PP&E

(62.3 k)(8.7 k)

Cash From Investing Activities

9.6 m4.5 m

Cash From Financing Activities

8.2 m10.1 m
Y, 2016

Financial Leverage

1.2 x

Rexahn Pharmaceuticals Operating Metrics

FY, 2016

Phase II Trials


Phase Preclinical


Patent Families


Patent Portfolios


Rexahn Pharmaceuticals Market Value History

Rexahn Pharmaceuticals Company Life and Culture

You may also be interested in